ImmunityBio (NASDAQ:IBRX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note released on Monday morning,Benzinga reports. D. Boral Capital currently has a $30.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

ImmunityBio Price Performance

NASDAQ IBRX opened at $2.56 on Monday. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -2.78 and a beta of 0.86. The stock’s fifty day moving average price is $4.07 and its 200 day moving average price is $4.41. ImmunityBio has a 1 year low of $2.50 and a 1 year high of $10.53.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds have recently added to or reduced their stakes in IBRX. Captrust Financial Advisors acquired a new position in shares of ImmunityBio in the 3rd quarter valued at about $41,000. Virtu Financial LLC acquired a new position in ImmunityBio in the third quarter valued at approximately $51,000. Algert Global LLC purchased a new stake in ImmunityBio in the 2nd quarter worth approximately $86,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after purchasing an additional 4,545 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in shares of ImmunityBio in the 2nd quarter valued at $105,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.